Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 9/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22891271 | 0.92 | DPP4 (0.42) | DPP4CHRM1MEN1KMT2ATP53 | |
| SCHEMBL13282679 | 0.91 | DPP4 (0.49) | DPP4FAAHCYP3A4ALDH1A1 | |
| SCHEMBL22891211 | 0.89 | DPP4 (0.41) | DPP4KMT2ATP53TDP1KDM4E | |
| SCHEMBL22891284 | 0.89 | DPP4 (0.41) | DPP4KMT2ATP53TDP1KDM4E | |
| SCHEMBL26148292 | 0.89 | DPP4 (0.44) | DPP4MEN1KMT2ATP53TDP1 | |
| SCHEMBL22030937 | 0.89 | DPP4 (0.41) | DPP4KMT2ATP53TDP1KDM4E | |
| SCHEMBL26148290 | 0.84 | DPP4 (0.41) | DPP4MEN1KMT2AKDM4EKDM2B | |
| SCHEMBL22891321 | 0.84 | DPP4 (0.41) | DPP4MEN1KMT2AKDM4EKDM2B | |
| SCHEMBL23514580 | 0.84 | CHRM1 (0.44) | CHRM1MEN1KMT2ATP53TDP1 | |
| SCHEMBL19432541 | 0.82 | DPP4 (0.44) | DPP4FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795170-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11649241-B2 | Pyrazolochlorophenyl compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795170-B2 | Therapeutic compounds, compositions and methods of use thereof | JAK2, JAK1, JAK3 | DPP4 1158/4885CHRM1 4855/4885MEN1 983/4885 |
| US-11649241-B2 | Pyrazolochlorophenyl compounds, compositions and methods of use thereof | JAK1, JAK2, JAK3 | DPP4 1302/4885CHRM1 4792/4885MEN1 1241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.